Abstract Background: Clostridium difficile infection (CDI) is a significant cause of morbidity and mortality in both the acute care setting and the wider healthcare system. The purpose of this study was to evaluate the in vitro activity of fidaxomicin against C. difficile isolates from a university teaching hospital in China. Methods: One hundred and one C. difficile isolates were collected and analyzed for toxin genes by multiplex PCR. The toxin gene positive strains were also typed by multilocus sequence typing (MLST) and PCR-ribotyping. The MICs of the isolates were determined against fidaxomicin, metronidazole, vancomycin, tigecycline and moxifloxacin, by the agar dilution method. Results: All the 101 isolates exhibited low MICs to fidaxomicin (0.032e1 mg/L), metronidazole (0.125e1 mg/L), vancomycin (0.25e2 mg/L) and tigecycline (0.016e0.5 mg/L). Tigecycline showed the lowest geometric mean MIC value (0.041 mg/L), followed by fidaxomicin (0.227 mg/L), metronidazole (0.345 mg/L), and vancomycin (0.579 mg/L). About 35% of the strains (n Z 35) were resistant to moxifloxacin, and the resistance rate to moxifloxacin for AÀBþCDTÀ isolates (85.0%) was much higher than that of AþBþCDTÀ (15.7%) and AÀBÀCDTÀ (29.2%) isolates (P < 0.001). The MIC values of fidaxomicin, metronidazole, vancomycin and moxifloxacin against the 3 ST1 isolates were higher than for other STs. All the 28 moxifloxacinresistant toxigenic isolates carried a mutation either in gyrA or/and gyrB. 
Introduction
Clostridium difficile infection (CDI) is a significant cause of morbidity and mortality in both the acute care setting and the wider healthcare system. 1, 2 The global increase in the incidence of CDI is partly driven by the emergence of hypervirulent C. difficile strain BI/NAP1/027 (restriction endonuclease analysis group BI, North American pulse-field type 1, PCR ribotype 027), placing a huge financial burden on health care systems worldwide. 3 In Asian countries, toxin A-negative toxin B positive (AÀBþ) strains are one of the major clones spreading in hospitals. 4 Furthermore, these strains show higher drug resistance rates compared to toxin A positive-toxin B positive (AþBþ) strains for the antibiotics clindamycin, erythromycin, levofloxacin, rifampicin, rifaximin and tetracycline. 5, 6 In China, CDI may be an underestimated problem due to limited laboratory capacity and low awareness. 7e9 Metronidazole and vancomycin are the mainstay options for CDI treatment. However, until recently, metronidazole was the only oral antibiotic approved for the treatment of CDI in China. And up to date, there is no oral formulation of vancomycin for CDI treatment. Clinicians in China often empirically treat severe CDI patients orally using a mixture of vancomycin injection with saline or glucose solution, leading to an uncertain therapeutic effect. In addition, both metronidazole and vancomycin are associated with treatment failure in about 3%e18% of patients, 10 and disease recurrence in about 30%. 11, 12 Therefore, developing and investigating new antibiotics for CDI treatment is of great importance.
Fidaxomicin is a new macrocyclic bactericidal antibiotic against C. difficile with a narrow spectrum activity against gram-positive anaerobes, leading to less disruption of the normal colonic anaerobic microflora. 13 This drug has recently been approved by the U.S. Federal Drug Administration and the European Medicines Agency for the treatment of CDI, 14 and may be an appropriate therapy for patients with severe or recurrent CDI. 15 However, little is known about the in vitro activity of fidaxomicin against C. difficile isolates from China. The aim of the present study was to investigate the in vitro activity of fidaxomicin and four other antimicrobial agents against recent clinical C. difficile isolates collected in Beijing, China.
Materials and methods

Bacterial isolates
A total of 101 non-duplicate C. difficile isolates, recovered from Peking Union Medical College Hospital (PUMCH) between August 2012 and July 2015, were included in the study. The isolates were consecutively collected from fecal specimens routinely sent to the clinical laboratory for C. difficile culture. Fresh fecal specimens were taken from patients aged !18 years with CDI symptoms, and for patients with multiple isolates, only the first isolate was included.
Toxin gene detection and multilocus sequence typing (MLST) analysis DNA extraction and subsequent toxin gene detection was carried out as previously described. 16 Capillary sequencerbased PCR ribotyping was performed as described by Indra et al. 17 and ribotypes were assigned by querying the results against WEBRIBO database (https://webribo.ages. at/). Other unknown ribotypes were serially named by using a letter designation. MLST was performed by sequencing seven house-keeping gene loci (adk, atpA, dxr, glyA, recA, sodA and tpi) as previously described by Griffiths et al., 18 and sequence types (STs) of C. difficile isolates were determined by querying on the official website (http://pubmlst.org/cdifficile/). Capillary sequencerbased PCR ribotyping and MLST were only performed on the toxigenic isolates.
Antimicrobial susceptibility testing
Antimicrobial susceptibility testing was performed by the agar dilution method according to Clinical and Laboratory Standards Institute (CLSI) guidelines (document M11-A8). 19 The following five antimicrobial agents were used: fidaxomicin, metronidazole, vancomycin, tigecycline and moxifloxacin. Fidaxomicin was obtained from ZheJiang Hisun Pharmaceutical CO.LTD (Taizhou, Zhejiang Province, China), and the remaining antimicrobial agents were obtained from National Institute for Food and Drug Control (Beijing, China). The resistance breakpoints for fidaxomicin have not been established, whilst the breakpoints for the remaining drugs were based on CLSI M100-S26 (metronidazole, !32 mg/L; moxifloxacin, !8 mg/L), EUCAST clinical breakpoints (vancomycin, >2 mg/L) or FDA document (tigecycline, !16 mg/L). 20, 21 Bacteroides fragilis ATCC 25285 and C. difficile ATCC 700057 were used for quality control.
Resistance gene detection
The gyrase subunits gyrA and gyrB, responsible for fluoroquinolone resistance, were amplified and sequenced as previously reported by Huang et al. 22 The fluoroquinolone resistance gene was only detected in toxin gene positive and moxifloxacin resistant isolates.
Statistical analyses
Statistical analyses were performed using SPSS software (version 17.0, IBM, New York, USA). The chi-square test was applied to compare categorical variables. The level of statistical significance was defined as P < 0.05.
Results
Toxin gene detection
Of the 101 strains studied, 51 (50.5%) were tcdA-positive, tcdB-positive and cdtA/cdtB-negative (AþBþCDTÀ), 20 (19.8%) were tcdA-negative, tcdB-positive and cdtA/cdtBnegative (AÀBþCDTÀ), 6 (5.9%) isolates were tcdA-positive, tcdB-positive and cdtA/cdtB-positive (AþBþCDTþ), while the remaining 24 (23.8%) isolates were tcdA-negative, tcdB-negative and cdtA/cdtB-negative (AÀBÀCDTÀ).
MLST and PCR-ribotype
MLST was performed on the 77 toxigenic C. difficile isolates. Fifteen STs and 18 ribotypes (RTs) were identified, and ST 54/RT 012 was the most common (n Z 13, 16.9%), followed by ST 37/RT 017 (n Z 11, 14.3%), ST 3/RT 001 and ST 81/RT A (n Z 9, 11.7% each). The relationship among the STs, PCR-ribotypes and toxin genes of the 77 toxigenic C. difficile isolates was shown in Table 1 .
Antimicrobial susceptibility
All the 101 strains were sensitive to metronidazole, vancomycin and tigecycline, with MIC 90 values of 0.5, 1 and 0.064 mg/L, respectively (Table 2 ). About 35% of the strains (n Z 35) were resistant to moxifloxacin. Tigecycline showed the lowest geometric mean (GM) MIC value (0.041 mg/L), followed by fidaxomicin (0.227 mg/L), metronidazole (0.345 mg/L), vancomycin (0.579 mg/L), and moxifloxacin (3.22 mg/L). The rate of moxifloxacin resistance was much higher among AÀBþCDTÀ isolates (85.0%) than among AþBþCDTÀ (15.7%) and AÀBÀCDTÀ (29.2%) isolates (P < 0.001). However, the GM MIC value of fidaxomicin against AÀBþCDTÀ isolates (0.171 mg/L) was lower than that of AþBþCDTÀ (0.241 mg/L) and AÀBÀCDTÀ (0.258 mg/L) isolates (Table 2) . Among the six AþBþCDTþ isolates, the MIC values for fidaxomicin, metronidazole, vancomycin and moxifloxacin against the 3 ST 1 isolates, were higher than that of the 3 ST 5 isolates (Table 3) .
Genes and mutations conferring moxifloxacin resistance
In order to investigate the mechanism of moxifloxacin resistance, gyrA and gyrB genes were amplified and sequenced on the 28 toxin gene positive and moxifloxacin resistant isolates. All the isolates carried a mutation either in gyrA or/and gyrB (Table 4) . Twelve isolates exhibited mutations in gyrA only, 2 in gyrB only, and the rest in both gyrA and gyrB. Overall, only one type of amino acid substitution in gyrA (Thr82/Ile) and three different types of substitutions in gyrB (Ser366/Ala, Asp426/Asn and Asp-426/Val), were identified. Mutations in gyrA (Thr82/Ile) and gyrB (Ser366/Ala, Asp426/Val) were identified in 5 of the 7 ST 81/RT A isolates, while gyrA (Thr82/Ile) and gyrB (Ser366/Ala) were identified in 9 of the 10 ST 37/RT 017 isolates.
Discussion
While the developed world has seen a significant increase in the number of scientific articles on CDI, the developing world including China, still lags behind on this subject. This may be attributed to low awareness of the CDI problem and limited laboratory capacity and surveillance in developing countries. 7e9 Recently, our group proposed a practical workflow for CDI diagnosis, compared different molecular typing methods, and described the first two ribotype 027 isolates in Beijing. 5, 9, 16 In this study, we performed antimicrobial susceptibility tests on C. difficile isolates from one hospital in China, against fidaxomicin and four other antimicrobial agents, which may provide some foundations for clinical treatment of CDI.
According to the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) guidelines, 23 metronidazole is the drug of choice for the initial episode of mild-to-moderate CDI, while vancomycin is the drug of choice for an initial episode of severe CDI. In this study, all the isolates were sensitive to metronidazole and vancomycin. However, recurrence occurs in approximately 30% of cases treated with metronidazole or vancomycin, 11, 12 and patients with at least one Antimicrobial activity of fidaxomicin against Clostridium difficileepisode of recurrent CDI have a 45%e65% chance of additional episodes. 24 Some studies have indicated that fidaxomicin has similar clinical cure rates to vancomycin and lower recurrence rates for CDI treatment. 25, 26 Our findings on the in vitro activity data for fidaxomicin, specifically the MICs, is similar with those published by the U.S-based national sentinel surveillance study and another different USA study. 27, 28 In contrast to the above, the fidaxomicin MICs reported in the present study are higher than that of the recently published pan-European surveillance program, and the ones reported in Spain, Sweden, Hungary and Taiwan.
29e33 To date, fidaxomicin has not been approved by China Food and Drug Administration for the treatment of CDI, and more studies involving multicentres are needed to investigate the clinical treatment outcome for Chinese CDI patients.
In the present study, tigecycline exhibited good in vitro activity against different toxin genotypes of C. difficile isolates with the lowest MIC value compared to other antibiotics. Intravenous tigecycline has only been used in a small number of patients with severe CDI refractory to standard therapy. 34 According to the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines, 35 intravenous tigecycline is only recommended as salvage therapy. In the present study, AÀBþCDTÀ strains, which are the most common C. difficile epidemic clones in China, Japan and Korea, 5,36,37 exhibited higher moxifloxacin drug resistance rates than AþBþCDTÀ and AÀBÀCDTÀ strains. In addition, the three ST 1 isolates showed higher MIC values for fidaxomicin, metronidazole, vancomycin and moxifloxacin, highlighting the significance of establishing a local surveillance network for CDI. However, it is worth mentioning that AÀBÀCDTÀ isolates have no pathogenic role in causing human disease, and treatment for such isolates in the stool of symptomatic patients is not suggested.
The gyrA and gyrB mutations were the principal mechanism conferring fluoroquinolone resistance in C. difficile in the present study. All the moxifloxacin-resistant isolates carried a mutation either in gyrA or gyrB or both. This finding is in agreement with those of two studies performed The gyrA substitution occurred more frequently than gyrB, and one type of substitution in gyrA (Thr82/Ile) was observed in the present investigation. Furthermore, double substitutions in gyrB were associated with a higher fluoroquinolone MIC (64 mg/L).
In conclusion, this study integrated the molecular epidemiology and antimicrobial activity of fidaxomicin against C. difficile isolates in mainland China. Fidaxomicin exhibited high antimicrobial activity against all C. difficile isolates tested, which shows promise as a new drug for treating Chinese CDI patients.
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